Doxazosin, an inferior antihypertensive agent?
Furberg
C D
CD
Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA. cfurberg@wfubmc.edu
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002752:Chlorthalidone / Q000627:therapeutic use; D018849:Controlled Clinical Trials as Topic; D004232:Diuretics / Q000627:therapeutic use; D017292:Doxazosin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D017410:Practice Guidelines as Topic; D028761:Withholding Treatment
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D004232:Diuretics; D017292:Doxazosin; D002752:Chlorthalidone